Literature DB >> 16904544

Effects of beta-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome.

Matti Viitasalo1, Lasse Oikarinen, Heikki Swan, Heikki Väänänen, Jere Järvenpää, Harri Hietanen, Jouko Karjalainen, Lauri Toivonen.   

Abstract

OBJECTIVES: We tested the hypothesis that in long-QT syndrome (LQT) type 1 (LQT1), beta-blocker therapy may decrease both the diurnal maximal T-wave peak to T-wave end interval (TPE) and the maximal ratio between late and early T-wave peak amplitude (T2/T1 ratio), which are electrocardiographic counterparts of transmural dispersion of repolarization (TDR) and early afterdepolarizations (EA), respectively.
BACKGROUND: Ventricular repolarization duration and increased TDR and EAs are the three electrophysiological components generating the high risk of ventricular arrhythmias and sudden death in the inherited LQT. In the most prevalent LQT1 form of LQT, treatment with beta-blockers reduces serious arrhythmia events dramatically without a known influence on QT interval duration. In experimental LQT1 models, beta-blockers decrease TDR and prevent EAs.
METHODS: We reviewed 24-h electrocardiographic recordings obtained before and during the treatment with beta-blockers from 24 genotyped LQT1 patients to record maximal TPE intervals and T2/T1 ratios as well as maximal and rate-adapted QT intervals using a computer-assisted program.
RESULTS: Treatment with beta-blockers decreased the maximal diurnal T2/T1 amplitude ratio from 3.0+/- 1.0 to 2.2 +/- 0.6 (p = 0.002). Beta-blockers also decreased both maximal TPE intervals and abrupt maximal QT intervals at heart rates higher than 85 beats/min, whereas QT intervals measured at steady-state conditions remained unchanged.
CONCLUSIONS: Prevention of abrupt increases of electrocardiographic TDR, EA, and ventricular repolarization duration at elevated heart rates may explain the favorable clinical effects of beta-blockers in LQT1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904544     DOI: 10.1016/j.jacc.2006.04.084

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Experience with bisoprolol in long-QT1 and long-QT2 syndrome.

Authors:  Christian Steinberg; Gareth J Padfield; Basil Al-Sabeq; Arnon Adler; John A Yeung-Lai-Wah; Charles R Kerr; Marc W Deyell; Jason G Andrade; Matthew T Bennett; Raymond Yee; George J Klein; Martin Green; Zachary W M Laksman; Andrew D Krahn; Santabhanu Chakrabarti
Journal:  J Interv Card Electrophysiol       Date:  2016-07-09       Impact factor: 1.900

2.  Epinephrine bolus test in detecting long QT syndrome mutation carriers with indeterminable electrocardiographic phenotype.

Authors:  Anna-Mari Hekkala; Heikki Swan; Matti Viitasalo; Heikki Väänänen; Lauri Toivonen
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-04       Impact factor: 1.468

Review 3.  The year of 2006 in electrocardiology.

Authors:  Shlomo Stern
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

4.  A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers.

Authors:  Naoki Toyota; Aya Miyazaki; Heima Sakaguchi; Wataru Shimizu; Hideo Ohuchi
Journal:  Heart Vessels       Date:  2014-06-11       Impact factor: 2.037

5.  Impaired cardiac sympathetic innervation in symptomatic patients with long QT syndrome.

Authors:  Peter Kies; Matthias Paul; Joachim Gerss; Lars Stegger; Gerold Mönnig; Otmar Schober; Thomas Wichter; Michael Schäfers; Eric Schulze-Bahr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-21       Impact factor: 9.236

6.  Rate-independent QT shortening during exercise in healthy subjects: terminal repolarization does not shorten with exercise.

Authors:  Prince J Kannankeril; Paul A Harris; Kris J Norris; Irfan Warsy; Phillip D Smith; Dan M Roden
Journal:  J Cardiovasc Electrophysiol       Date:  2008-07-28

7.  Long QT syndrome: A therapeutic challenge.

Authors:  Maully Shah; Christopher Carter
Journal:  Ann Pediatr Cardiol       Date:  2008-01

8.  Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome.

Authors:  Fabrice Extramiana; Pierre Maison-Blanche; Isabelle Denjoy; Patrick De Jode; Anne Messali; Jean-Philippe Labbé; Antoine Leenhardt
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

9.  The high frequency relationship: implications for torsadogenic hERG blockers.

Authors:  P Champeroux; J Y Le Guennec; S Jude; C Laigot; A Maurin; M L Sola; J S L Fowler; S Richard; J Thireau
Journal:  Br J Pharmacol       Date:  2016-01-14       Impact factor: 8.739

10.  T-Peak to T-End Improvements After Beta-Blocker Administration in Peripartum Cardiomyopathy Patients.

Authors:  Chaerul Achmad; Mohammad Iqbal; Giky Karwiky; Hawani Sasmaya Prameswari; Mega Febrianora
Journal:  Cardiol Res       Date:  2020-05-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.